| Literature DB >> 35991646 |
Chuanrui Sun1, Baoyu Qi1, Xinyi Huang2, Ming Chen1, Zikai Jin1, Yili Zhang3, Liguo Zhu1, Xu Wei1.
Abstract
Purpose: Baduanjin (BDJ) exercise is a traditional exercise that combines breathing, body movement, meditation and awareness to help delay the onset and progression of senile degenerative musculoskeletal diseases, such as osteoporosis (OP). The aim of this meta-analysis is to evaluate the efficacy of BDJ exercise, and preliminarily infer its effective mechanism in the treatment of OP.Entities:
Keywords: Baduanjin exercise; Chinese qigong; evidence-based medicine; meta-analysis; osteoporosis; trial sequential analysis
Year: 2022 PMID: 35991646 PMCID: PMC9381703 DOI: 10.3389/fmed.2022.935961
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
FIGURE 1PRISMA flow diagram. PRISMA, preferred reporting items for systematic review and meta-analysis; RCTs, randomized controlled trials; P, population; I, intervention; C, comparison; O, outcome.
Characteristics of included trials.
| Study ID | Country | Types | Size | Gender | Intervention | Intervention details | Outcomes | ||||
| C | T | M | F | C | T | C | T | ||||
| Wang and Sha ( | China | PMOP | 36 | 36 | / | 72 | Blank | BDJ exercise | None | 50 min each time, twice a day, 5 days a week for 3 months | (1) BMD (L1–L4 and femoral neck) |
| Miao and Wang ( | China | PMOP | 12 | 12 | / | 24 | Blank | BDJ exercise | None | 60 min each time, once a day, 6 days a week for 12 months | (1) BMD (L2, Distal 1/3 of ulna and radius) |
| Li ( | China | PMOP | 25 | 21 | / | 46 | Blank | BDJ exercise | None | 70 min each time, five times a week for 24 weeks | (1) BMD (L2–L4 and dominant proximal femur) |
| Cai et al. ( | China | PMOP | 30 | 30 | / | 60 | Conventional treatment | Conventional treatment + BDJ exercise | Calcium carbonate and vitamin D3 tablets (one time a day, 0.6 g each time for 12 months) | Twice per day, 5 days a week for 6 months | (1) BMD (L2-L4) |
| Su and Deng ( | China | PMOP | 40 | 40 | / | 80 | Conventional treatment | Conventional treatment + BDJ exercise | (1) Alendronate sodium (70 mg/time, 1 time/week) | 45–60 min each time, twice per day, 5 days a week for 6 months | (1) BMD (L2–L4) |
| Zhang et al. ( | China | PMOP | 36 | 36 | / | 72 | Conventional treatment | Conventional treatment + BDJ exercise | Calcium carbonate and vitamin D3 Tablets (one time a day, 0.6 g each time for 12 months) | Twice per day, 5 days a week for 12 months | (1) BMD (L2–L4 and left femoral neck, the baseline, the 12 weeks and 24 weeks) |
| Chen et al. ( | China | PMOP | 43 | 44 | / | 87 | Blank | BDJ exercise | None | Learn for 2 weeks, 3 days a week for 12 weeks | (1) BMD |
| Liu ( | China | POP | 30 | 30 | 31 | 29 | Conventional treatment | Conventional treatment + BDJ exercise | Such as calcium preparations, etc. | 60 min per day, 6 days a week for 6 months | (1) BMD |
| Li et al. ( | China | SOP | 35 | 38 | / | / | Blank | BDJ targeted exercise | Simply distributing fall prevention health education brochures | Five times a week, including twice targeted exercise, three times independent exercise for 24 weeks | (1) BMD (L2-L4 and double hip, the baseline, 12th weeks and the 24th weeks) |
| Li et al. ( | China | SOP | 35 | 37 | / | / | Blank | BDJ independent exercise | Simply distributing fall prevention health education brochures | Distributing BDJ exercise CDs and practice wall charts | (1) BMD (L2–L4 and double hip, the baseline, 12th weeks and the 24th weeks) |
| Sun et al. ( | China | SOP | 30 | 30 | 15 | 45 | Conventional treatment | Conventional treatment + BDJ exercise | Alfacalcidol (0.5 μg/day), calcium (0.6 g/day), alendronate (70 mg/week) | 50 min each time, three times a week for 12 months | (1) BMD (L2–L4, femoral neck and double hip) |
| Kuang ( | China | SOP | 41 | 41 | / | / | Conventional treatment | Conventional treatment + BDJ exercise | Calcium carbonate and vitamin D3 Tablets (two time a day, one tablets each time for 6 months) | 60 min each time, twice daily for 3 months | (1) BMD (L2-L4, femoral neck and double hip) |
| Sun et al. ( | China | SOP (male) | 25 | 18 | 43 | / | Conventional treatment | Conventional treatment + BDJ exercise | Calcium, vitamin D, alendronate and salmon calcitonin. Intervention for 6 months | More than 20 times in 4 weeks for 6 months | (1) BMD (L1-L4 and femoral neck) |
| Li et al. ( | China | SOP | 44 | 44 | 28 | 60 | Conventional treatment | Conventional treatment + BDJ exercise | Calcium carbonate and vitamin D3 Tablets and salmon calcitonin | 30–40 min each time, once daily for 6 months | (1) ECLSB (Eyes closed and single legged standing balance capacity) |
C, control group; T, treatment group; M, male; F, female; PMOP, postmenopausal osteoporosis; SOP, senile osteoporosis; POP, primary osteoporosis.
FIGURE 2Risk of bias graph.
The results of all outcomes: all participants.
| Outcomes | Number of study | Risk ratio or mean difference (95% CI) | Quality | ||||
| BMD | Spine | 9 | 0.20 [0.09, 0.31] | <0.0001 | <0.00001 | 86 | Low |
| Femur | 6 | 0.05 [−0.01, 0.12] | 0.09 | <0.00001 | 87 | Low | |
| Hip | 3 | 0.15 [−0.23, 0.54] | 0.01 | 0.61 | 0 | Low | |
| VAS | 4 | −0.64 [−0.91, −0.38] | <0.00001 | 0.06 | 60 | Low | |
| BBS | 5 | 5.05 [3.17, 6.93] | <0.00001 | 0.004 | 74 | Low | |
| Ca | 3 | 0.02 [−0.06, 0.10] | 0.63 | 0.11 | 55 | Low | |
| P | 3 | 0.03 [−0.01, 0.06] | 0.19 | 0.97 | 0 | Low | |
| ALP | 4 | 1.63 [−2.15, 5.40] | 0.40 | 0.09 | 53 | Low | |
| BGP | 2 | 0.81 [0.64, 0.99] | <0.00001 | 0.39 | 0 | Low | |
ALP, alkaline phosphatase; BBS, Berg balance scale; BGP, bone gla protein; BMD, bone mineral density; Ca, serum calcium; P, serum phosphorus; RCTs, randomized controlled trials; VAS, visual analog scale.
FIGURE 3The bone mineral density (BMD) results of all participants for three subgroups: the control group vs. the intervention group.
The results of all outcomes for five subgroups: the control group vs. the intervention group.
| Group | Subgroups | Categories | Outcomes | Number of study | Risk ratio or mean difference (95% CI) | Quality | ||||
| BDJ exercise | PMOP | Primary outcome | BMD | Spine | 4 | 0.60 [0.30, 0.90] | <0.0001 | 0.31 | 17 | Low |
| Femur | 1 | 0.01 [−0.06, 0.08] | 0.77 | Low | ||||||
| Hip | 2 | 0.57 [−0.14, 1.27] | 0.11 | 0.51 | 0 | Low | ||||
| Secondary outcomes | VAS | 1 | −1.71 [−1.75, −1.67] | <0.00001 | Low | |||||
| BBS | – | |||||||||
| Ca | 1 | 0.13 [0.01, 0.26] | 0.04 | Low | ||||||
| P | 1 | 0.03 [−0.07, 0.13] | 0.57 | Low | ||||||
| ALP | 2 | 5.25 [1.50, 9.01] | 0.006 | 0.72 | 0 | Low | ||||
| BGP | 1 | 2.26 [−1.07, 5.59] | 0.18 | Low | ||||||
| SOP | Primary outcome | BMD | Spine | 2 | 0.32 [−0.62, 1.27] | 0.5 | 0.004 | 88 | Low | |
| Femur | – | |||||||||
| Hip | 2 | 0.57 [−0.14, 1.27] | 0.11 | 0.51 | 0 | Low | ||||
| Secondary outcomes | VAS | – | ||||||||
| BBS | 2 | 3.42 [1.99, 4.85] | 0.004 | 0.1 | 63 | Low | ||||
| Ca | – | |||||||||
| P | – | |||||||||
| ALP | – | |||||||||
| BGP | – | |||||||||
| BDJ exercise | PMOP | Primary outcome | BMD | Spine | 3 | 0.68 [0.25, 1.11] | 0.002 | 0.09 | 58 | Low |
| Femur | 1 | 0.00 [−0.46, 0.46] | 1 | Low | ||||||
| Hip | – | |||||||||
| Secondary outcomes | VAS | 2 | −1.37 [−1.40, −1.35] | <0.00001 | <0.00001 | 97 | Low | |||
| BBS | 1 | 4.47 [0.12, 8.82] | 0.04 | Low | ||||||
| Ca | 2 | −0.02 [−0.07, 0.04] | 0.58 | 0.85 | 0 | Low | ||||
| P | 2 | 0.02 [−0.02, 0.07] | 0.24 | 0.81 | 0 | Low | ||||
| ALP | 2 | −0.96 [−4.06, 2.13] | 0.54 | 0.99 | 0 | Low | ||||
| BGP | 1 | 0.81 [0.63, 0.99] | <0.00001 | Low | ||||||
| SOP | Primary outcome | BMD | Spine | 3 | 1.19 [−0.42, 2.80] | 0.15 | <0.00001 | 96 | Low | |
| Femur | 2 | 0.01 [−0.00, 0.03] | 0.14 | 0.27 | 18 | Low | ||||
| Hip | 1 | 0.01 [0.00, 0.02] | 0.03 | Low | ||||||
| Secondary outcomes | VAS | 3 | −0.67 [−1.07, −0.27] | 0.001 | 0.02 | 73 | Low | |||
| BBS | 2 | 5.95 [4.85, 7.04] | <0.0001 | 0.03 | 80 | Low | ||||
| Ca | – | |||||||||
| P | – | |||||||||
| ALP | – | |||||||||
| BGP | – | |||||||||
| POP | Primary outcome | BMD | Spine | 1 | 0.21 [0.16, 0.26] | <0.00001 | Low | |||
| Femur | 1 | 0.23 [0.17, 0.28] | <0.00001 | Low | ||||||
| Hip | – | |||||||||
| Secondary outcomes | VAS | – | ||||||||
| BBS | – | |||||||||
| Ca | – | |||||||||
| P | – | |||||||||
| ALP | – | |||||||||
| BGP | – | |||||||||
PMOP, postmenopausal osteoporosis; SOP, senile osteoporosis; POP, primary osteoporosis; ALP, alkaline phosphatase; BBS, Berg balance scale; BGP, bone gla protein; BMD, bone mineral density; Ca, serum calcium; P, serum phosphorus; RCTs, randomized controlled trials; VAS, visual analog scale.
FIGURE 4Funnel plot analysis: publication bias.
FIGURE 5The potential mechanism of Baduanjin (BDJ) exercise.
Comparison with other previous meta-analyses.
| Author | Li et al. ( | Yu ( | The present meta-analysis |
| Number of RCTs | 15 | 4 | 13 |
| Participants | Osteoporosis | Senile osteoporosis | Osteoporosis |
| Search strategy until | January 2019 | January 2020 | April 2022 |
| Protocol registered |
|
| Applied |
| Trial sequential analysis |
|
| Applied |
| Outcomes | BMD (lumbar spine, femoral neck), VAS, BGP, ALP, and Ca | BMD (lumbar spine, femoral neck, Ward’s triangle, and greater trochanter), ALP | BMD (lumbar spine, femoral neck, hip), VAS, BBS, Ca, P, ALP, and BGP |
ALP, alkaline phosphatase; BBS, Berg balance scale; BGP, bone gla protein; BMD, bone mineral density; Ca, serum calcium; P, serum phosphorus; RCTs, randomized controlled trials; VAS, visual analog scale.